id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-6700-0008,FDA,FDA-2017-E-6700,Notice of Final Determination - Revised,Other,Letter(s),2024-03-25T04:00:00Z,2024,3,2024-03-25T04:00:00Z,,2024-03-25T22:58:11Z,,0,0,090000648646a192
FDA-2017-E-6700-0007,FDA,FDA-2017-E-6700,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-09-17T04:00:00Z,2019,9,2019-09-17T04:00:00Z,,2019-09-17T13:40:07Z,,0,0,0900006483f86c08
FDA-2017-E-6700-0006,FDA,FDA-2017-E-6700,Determinations of Regulatory Review Periods for Purposes of Patent Extensions: RYDAPT,Notice,Determinations,2018-12-28T05:00:00Z,2018,12,2018-12-28T05:00:00Z,2019-06-27T03:59:59Z,2024-03-07T21:04:21Z,2018-28216,0,0,09000064839cbfba
FDA-2017-E-6700-0005,FDA,FDA-2017-E-6700,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,,2018-12-21T17:40:06Z,,0,0,09000064839c0478
FDA-2017-E-6700-0004,FDA,FDA-2017-E-6700,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T12:54:30Z,,0,0,090000648378ad57
FDA-2017-E-6700-0003,FDA,FDA-2017-E-6700,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2018-01-10T05:00:00Z,2018,1,2018-01-10T05:00:00Z,,2018-01-10T13:12:27Z,,0,0,0900006482dd35f2
FDA-2017-E-6700-0002,FDA,FDA-2017-E-6700,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2017-12-01T05:00:00Z,2017,12,2017-12-01T05:00:00Z,,2017-12-01T14:36:28Z,,0,0,0900006482cca18d
FDA-2017-E-6700-0001,FDA,FDA-2017-E-6700,Patent Extension Application from Novartis Pharmaceuticals Corp,Other,Application,2017-12-01T05:00:00Z,2017,12,2017-12-01T05:00:00Z,,2017-12-01T14:30:25Z,,0,0,0900006482cca189